Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Narasimhan: Novartis' Specialized Portfolio Will Lead To Bigger Breakthroughs And Greater Value

Executive Summary

At Novartis’s first R&D day since he took the helm, new CEO Vas Narasimhan told Scrip about how the company plans to build value through its newly acquired breakthrough technologies and what deals it is looking for next.

Advertisement

Related Content

Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy
Big Statement By Aurobindo As It Seals $1bn Sandoz US Deal
Novartis Sees The Light And Plumps For Alcon Spin-Off
Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition
Novartis Deal Gives Xencor $150m Up Front, Up To $2.41bn In Milestone Fees

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124128

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel